Know Cancer

forgot password

Fast Spectral Imaging Device for Tumor Margin Mapping

18 Years
Not Enrolling
Breast Cancer

Thank you

Trial Information

Fast Spectral Imaging Device for Tumor Margin Mapping

Inclusion Criteria:

- Patients undergoing a partial mastectomy or mastectomy for the treatment of an
invasive or non-invasive breast malignancy

- Age > 18

- Clinically detectable disease either by physical examination or radiographic studies

- Patients of all ethnic and gender groups will be included. Protocol accrual will be
reviewed annually to include a determination of minority and gender representation.
If accrual demonstrates under representation of any group with comparison to disease
incidence in that group, appropriate measures will be undertaken to increase
participation of patients of that minority or gender group.

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients considered in "vulnerable" populations

Type of Study:


Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To perform a critical evaluation of the device in a practical clinical setting

Outcome Description:

(1) In order to define the effective post-excision time window in which the device must be used, which ultimately has bearings on the final product indications for use. (2)To analyze the different methods of implementation of the technology.

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Nimmi Ramanujam, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Duke University


United States: Food and Drug Administration

Study ID:




Start Date:

September 2009

Completion Date:

September 2011

Related Keywords:

  • Breast Cancer
  • breast cancer
  • breast carcinoma in situ
  • ductal breast carcinoma in situ
  • invasive carcinoma
  • invasive ductal carcinoma
  • invasive lobular carcinoma
  • Breast Neoplasms



Duke University Medical CenterDurham, North Carolina  27710